0000899243-21-002759.txt : 20210121
0000899243-21-002759.hdr.sgml : 20210121
20210121192428
ACCESSION NUMBER: 0000899243-21-002759
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210119
FILED AS OF DATE: 20210121
DATE AS OF CHANGE: 20210121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Miller Edward
CENTRAL INDEX KEY: 0001619252
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 21543314
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACEUTICALS, INC
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-19
0
0001754068
Allovir, Inc.
ALVR
0001619252
Miller Edward
C/O ALLOVIR, INC.
139 MAIN STREET, SUITE 500
CAMBRIDGE
MA
02142
0
1
0
0
General Counsel
Common Stock
2020-12-01
5
G
0
E
41514
0.00
D
166051
D
Common Stock
2020-12-01
5
G
0
E
41514
0.00
A
198811
I
See Footnote
Common Stock
2021-01-19
4
A
0
28000
0.00
A
194051
D
Stock Option (Right to Buy)
42.15
2021-01-19
4
A
0
52000
0.00
A
2031-01-19
Common Stock
52000
52000
D
On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.
25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.
/s/ Brett Hagen, as Attorney-in-Fact
2021-01-21